Abstract:Background Glioblastoma (GBM) is the most prominent and aggressive primary brain tumor in adults. Anoikis is a specific form of programmed cell death that plays a key role in tumor invasion and metastasis. The presence of anti-anoikis factors is associated with tumor aggressiveness and drug resistance. Methods The non-negative matrix factorization algorithm was used for effective dimension reduction for integrated datasets. Differences in the tumor microenvironment (TME), stemness indices, and clinical characteristics between the two clusters were analyzed. Difference analysis, weighted gene coexpression network analysis (WGCNA), univariate Cox regression, and least absolute shrinkage and selection operator regression were leveraged to screen prognosis-related genes and construct a risk score model. Immunohistochemistry was performed to evaluate the expression of representative genes in clinical specimens. The relationship between the risk score and the TME, stemness, clinical traits, and immunotherapy response was assessed in GBM and pancancer. Results Two definite clusters were identified on the basis of anoikis-related gene expression. Patients with GBM assigned to C1 were characterized by shortened overall survival, higher suppressive immune infiltration levels, and lower stemness indices. We further constructed a risk scoring model to quantify the regulatory patterns of anoikis-related genes. The higher risk score group was characterized by a poor prognosis, the infiltration of suppressive immune cells and a differentiated phenotype, whereas the lower risk score group exhibited the opposite effects. In addition, patients in the lower risk score group exhibited a higher frequency of isocitrate dehydrogenase (IDH) mutations and a more sensitive response to immunotherapy. Drug sensitivity analysis was performed, revealing that the higher risk group may benefit more from drugs targeting the PI3K/mTOR signaling pathway. Conclusion We revealed potential relationships between anoikis-related genes and clinical features, TME, stemness, IDH mutation, and immunotherapy and elucidated their therapeutic value.

Cell senescence-associated genes predict the malignant characteristics of glioblastoma

Advanced in the therapy-induced senescence in glioblastoma

Cellular senescence in malignant cells promotes tumor progression in mouse and patient Glioblastoma

Ccnb2/Sasp/Cathepsin B & Pge2 Axis Induce Cell Senescence Mediated Malignant Transformation

Mechanistic insights into super-enhancer-driven genes as prognostic signatures in patients with glioblastoma

Cell aging related genes can be used to characterize clinical prognoses and further stratify diffuse gliomas

Cellular senescence in glioma

Cancer Stem Cells in Glioblastoma—molecular Signaling and Therapeutic Targeting

Identification and validation of an anoikis-associated gene signature to predict clinical character, stemness, IDH mutation, and immune filtration in glioblastoma

Tumour Cell Dormancy As A Contributor To The Reduced Survival Of Gbm Patients Who Received Standard Therapy

Expression and prognosis of cellular senescence genes in head and neck squamous cell carcinoma

Bmi-1 induces radioresistance by suppressing senescence in human U87 glioma cells.

Autophagy inhibition signals through senescence to promote tumor suppression

Clinical characteristics and prognosis of patients with glioblastoma: A review of survival analysis of 1674 patients based on SEER database

Tumor cell senescence response produces aggressive variants

Irradiation induces glioblastoma cell senescence and senescence-associated secretory phenotype

Integrative analysis of single-cell transcriptomics reveals age-associated immune landscape of glioblastoma

Association Between Diverse Cell Death Patterns Related Gene Signature and Prognosis, Drug Sensitivity, and Immune Microenvironment in Glioblastoma

Cell Senescence and Its Critical Role in Antitumor Research

Targeting role of glioma stem cells for glioblastoma multiforme.

Resveratrol Suppresses Epithelial-Mesenchymal Transition in GBM by Regulating Smad-Dependent Signaling